Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 27, 2006

Argos Awarded $21M to Develop its Personalized HIV Therapy

  • Argos Therapeutics has been awarded a five-year, $21-million NIH contract to develop HIV immunotherapy candidates. Argos is developing personalized, RNA-loaded dendritic cell immunotherapy products designed to train the patient’s immune system to recognize, target, and destroy unique features of their disease.

    The goal of the contract, issued by the NIAID, is to determine the immunogenicity of Argos’ HIV immunotherapy candidate currently in clinical trials and subsequently develop more potent product candidates.

    Argos has partnered with a number of leading institutions which will participate in the development program. The award will cover substantially all costs associated with the development of such HIV immunotherapies, as well as portions of costs related to Argos’ current HIV candidate development. 

     



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »